Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Scientists discover why bats survive deadly viruses without getting sick July 29, 2026 Dynamic BH3 profiling offers personalized lung cancer therapies April 9, 2025 Study links cord blood lipid levels to early ADHD and autism symptoms January 12, 2024